BRIEF-Biomerieux Gets U.S. FDA Clearance For New Version Of BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
ReutersFeb 11, 2025 6:53 AM
Feb 11 (Reuters) - Biomerieux SA BIOX.PA:
ANNOUNCED ON TUESDAY IT RECEIVED U.S. FDA CLEARANCE FOR NEW VERSION OF MOLECULAR TEST TARGETING CAUSES OF GASTROENTERITIS, BIOFIRE® FILMARRAY® GASTROINTESTINAL (GI) PANEL MID
BIOFIRE® GASTROINTESTINAL (GI) PANEL MID TO BE COMMERCIALLY AVAILABLE IN U.S. AT END OF H1 2025
Source text: https://tinyurl.com/4vv6xxfd
Further company coverage: BIOX.PA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
SoundHound Analysis: Will This Overlooked AI Stock Be the Surprise Winner of 2026?
While buying SoundHound stock, you may need to look at key indicators that will help you tell the noise from the signals.TradingKey
10 hours ago
Stock Market Crash 2026: What Fed Signals and Economic Data Mean for Investors
TradingKey - The possibility of a stock market crash occurring in 2026 is becoming increasingly likely as investor sentiment continues to decline.TradingKey
Thu, Feb 19
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.TradingKey
Thu, Feb 19
